1.27
price down icon8.63%   -0.12
after-market Dopo l'orario di chiusura: 1.27
loading
Precedente Chiudi:
$1.39
Aprire:
$1.35
Volume 24 ore:
1.41M
Relative Volume:
0.68
Capitalizzazione di mercato:
$65.43M
Reddito:
-
Utile/perdita netta:
$-97.22M
Rapporto P/E:
-0.9203
EPS:
-1.38
Flusso di cassa netto:
$-82.44M
1 W Prestazione:
-25.29%
1M Prestazione:
-48.79%
6M Prestazione:
-95.29%
1 anno Prestazione:
-93.83%
Intervallo 1D:
Value
$1.25
$1.37
Intervallo di 1 settimana:
Value
$1.25
$1.79
Portata 52W:
Value
$1.25
$42.20

Cassava Sciences Inc Stock (SAVA) Company Profile

Name
Nome
Cassava Sciences Inc
Name
Telefono
512-501-2444
Name
Indirizzo
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
SAVA's Discussions on Twitter

Confronta SAVA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SAVA
Cassava Sciences Inc
1.27 65.43M 0 -97.22M -82.44M -1.38
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 125.55B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 67.78B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 36.24B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.99B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.77B 3.81B -644.79M -669.77M -6.24

Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-26 Downgrade H.C. Wainwright Buy → Neutral
2024-10-08 Aggiornamento H.C. Wainwright Neutral → Buy
2024-07-01 Downgrade H.C. Wainwright Buy → Neutral
2022-11-16 Downgrade B. Riley Securities Buy → Neutral
2021-07-15 Downgrade Cantor Fitzgerald Overweight → Neutral
2021-07-07 Reiterato Maxim Group Buy
2021-04-27 Iniziato B. Riley Securities Buy
2021-02-16 Reiterato H.C. Wainwright Buy
2020-10-23 Iniziato Cantor Fitzgerald Overweight
2020-09-23 Aggiornamento H.C. Wainwright Neutral → Buy
2020-05-18 Downgrade H.C. Wainwright Buy → Neutral
2020-05-15 Downgrade Maxim Group Buy → Hold
2020-01-10 Reiterato Maxim Group Buy
Mostra tutto

Cassava Sciences Inc Borsa (SAVA) Ultime notizie

pulisher
Apr 02, 2025

SAVA stock touches 52-week low at $1.34 amid market challenges - Investing.com Australia

Apr 02, 2025
pulisher
Apr 01, 2025

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs - Being Patient

Mar 31, 2025
pulisher
Mar 31, 2025

Is the Future Bleak for SAVA Stock Following Another Setback? - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful - MSN

Mar 31, 2025
pulisher
Mar 30, 2025

Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus - MSN

Mar 30, 2025
pulisher
Mar 26, 2025

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer’s drug By Reuters - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study - MSN

Mar 26, 2025
pulisher
Mar 26, 2025

Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Zacks Investment Research

Mar 26, 2025
pulisher
Mar 26, 2025

Cassava ends Alzheimer’s program after simufilam fails again - The Pharma Letter

Mar 26, 2025
pulisher
Mar 26, 2025

Cassava ends simufilam Alzheimer’s programme after second Phase III failure - Yahoo Finance

Mar 26, 2025
pulisher
Mar 25, 2025

Rodman & Renshaw maintains Sell rating on Cassava Sciences stock By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

SAVA stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Sector Update: Health Care Stocks Fall Late Afternoon - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

Sector Update: Health Care - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

Rodman & Renshaw maintains Sell rating on Cassava Sciences stock - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Top Midday Decliners - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Sciences Stock: Alzheimer Drug Fails, Program Terminated - Sharewise

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Drops 19% Pre-Market After Decision to End Alzheimer's Program - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam - BioSpace

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava ends work on Alzheimer’s drug; Alumis gets $40M upfront from Kaken - Endpoints News

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study - NewsBreak: Local News & Alerts

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava stock down as Alzheimer’s program ends (SAVA:NASDAQ) - Seeking Alpha

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Sciences shuts down Alzheimer's programshares plummet - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

SAVA stock touches 52-week low at $2.15 amid market challenges - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Sciences' Phase 3 Study of Simufilam Showed No Benefit for Alzheimer's Patients - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava to discontinue development of Alzheimer’s disease drug - KFGO

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Sciences ends Alzheimer’s treatment development after unsuccessful trials By Investing.com - Investing.com UK

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Sciences stock tumbles after Alzheimer’s drug fails key study By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava to discontinue development of Alzheimer's disease drug - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Cassava Sciences Reports Topline Phase 3 Refocus-Alz Data - MarketScreener

Mar 25, 2025
pulisher
Mar 21, 2025

Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSAVA - ACCESS Newswire

Mar 21, 2025
pulisher
Mar 20, 2025

Cassava Sciences: Downside From Alzheimer's Results Still Possible Despite New Developments - Seeking Alpha

Mar 20, 2025
pulisher
Mar 20, 2025

Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire

Mar 20, 2025
pulisher
Mar 18, 2025

Cassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey

Mar 18, 2025
pulisher
Mar 15, 2025

10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey

Mar 15, 2025
pulisher
Mar 12, 2025

Cassava Sciences revises executive bonus plan By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava S - GuruFocus.com

Mar 12, 2025
pulisher
Mar 11, 2025

Cassava Sciences Amends Bonus Plan After Court Settlement - TipRanks

Mar 11, 2025

Cassava Sciences Inc Azioni (SAVA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Capitalizzazione:     |  Volume (24 ore):